Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 6;24(1):30.
doi: 10.1186/s12941-025-00798-4.

Mortality and exacerbations in bronchiectasis patients with carbapenem-resistant Pseudomonas aeruginosa isolation: a long-term retrospective cohort study

Jibo Sun  1   2 , Qingqing Jia  1   2 , Wenting Lv  1   2 , Shijie Zhang  1   2 , Sitong Liu  1   2 , Dongguang Wang  1   2 , Lian Wang  1   2 , Xiang Tong  1   2 , Jiehao Chen  3 , Xiaoting Chen  3 , Yongjiang Tang  4   5 , Hong Fan  6   7
Affiliations

Mortality and exacerbations in bronchiectasis patients with carbapenem-resistant Pseudomonas aeruginosa isolation: a long-term retrospective cohort study

Jibo Sun et al. Ann Clin Microbiol Antimicrob. .

Abstract

Background: Few studies have investigated the impact of carbapenem-resistant Pseudomonas aeruginosa (CRPA) on long-term outcomes in bronchiectasis. This study aimed to analyze acute exacerbations and mortality in bronchiectasis patients with CRPA isolation.

Methods: This retrospective study included bronchiectasis patients with PA-positive cultures from January 1, 2014, to July 31, 2023, at West China Hospital of Sichuan University. PA was isolated from sputum or bronchoalveolar lavage fluid (BALF) and classified into CRPA and non-CRPA groups based on antimicrobial susceptibility testing. Multivariate logistic regression was used to assess risk factors for acute exacerbations, while multivariate Cox regression identified independent risk factors for all-cause and cause-specific mortality.

Results: Among 564 patients with PA-positive isolates, 143 (25.36%) harbored CRPA strains. CRPA isolation was associated with an increased risk of acute exacerbations (adjusted odds ratio [aOR] 2.072, p = 0.001), while antibiotic treatment reduced the risk of exacerbations (aOR 0.439, p = 0.011). CRPA isolation was an independent risk factor for all-cause (adjusted hazard ratio [aHR] 1.488, p = 0.031) and cause-specific mortality (aHR 1.882, p = 0.010). The 1-, 3-, 5-, and 7-year cause-specific survival rates in the CRPA group were 88.6%, 79.8%, 73.2%, and 68.0%, respectively, versus 95.4%, 91.0%, 85.6%, and 81.8% in the non-CRPA group (p = 0.001).

Conclusion: CRPA isolation was significantly associated with an increasing risk of acute exacerbations, overall and cause-specific mortality. These findings underscored the urgent need to strengthen antibiotic stewardship to reduce the emergence of CRPA and to implement early detection and targeted management strategies to improve outcomes for patients with CRPA.

Keywords: Bronchiectasis; CRPA; Exacerbations; Mortality.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study was approved by the Ethics Committee on Biomedical Research at the West China Hospital of Sichuan University (No. 2022455). Informed consent was also waived by the ethics committee of the West China Hospital. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Multivariate logistic regression of risk factors for acute exacerbations
Fig. 2
Fig. 2
Multivariate Cox proportional hazards regression of risk factors for all-cause mortality
Fig. 3
Fig. 3
Multivariate Cox proportional hazards regression of risk factors for cause-specific mortality
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Chalmers JD, Polverino E, Crichton ML, Ringshausen FC, De Soyza A, Vendrell M, Burgel PR, Haworth CS, Loebinger MR, Dimakou K, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir Med. 2023;11(7):637–49. - PubMed
    1. Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, Smeeth L, Brown JS. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016;47(1):186–93. - PMC - PubMed
    1. Lin JL, Xu JF, Qu JM. Bronchiectasis in China. Ann Am Thorac Soc. 2016;13(5):609–16. - PubMed
    1. Feng J, Sun L, Sun X, Xu L, Liu L, Liu G, Wang J, Gao P, Zhan S, Chen Y, et al. Increasing prevalence and burden of bronchiectasis in urban Chinese adults, 2013–2017: a nationwide population-based cohort study. Respir Res. 2022;23(1):111. - PMC - PubMed
    1. Roberts JM, Goyal V, Kularatna S, Chang AB, Kapur N, Chalmers JD, Goeminne PC, Hernandez F, Marchant JM, McPhail SM. The economic burden of bronchiectasis: a systematic review. Chest. 2023;164(6):1396–421. - PubMed

MeSH terms

LinkOut - more resources